Recent advances of Pin1 inhibitors as potential anticancer agents

Bai, Yiru; Yuan, Ziqiao; Yuan, Shuo; He, Zhangxu

doi:10.1016/j.bioorg.2024.107171

Bioorganic Chemistry

2024

DOI: 10.1016/j.bioorg.2024.107171

|View full text |Cite

Recent advances of Pin1 inhibitors as potential anticancer agents

Yiru Bai,

Ziqiao Yuan,

Shuo Yuan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Covalent binding of withanolides to cysteines of protein targets

Bailly

2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Covalent binding of withanolides to cysteines of protein targets

Bailly

2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs

Liu,

Chen,

Chen

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

Peptidyl-prolyl cis–trans isomerase NIMA-interacting 1 (PIN1) has emerged as a promising therapeutic target for cancer treatment. However, the current PIN1 inhibitors have shown limited efficacy in animal models, leaving the question of whether PIN1 is a proper oncologic target still unanswered. By screening a 1 trillion DNA-encoded library (DEL), we identified novel nonacidic compounds. Among resynthesized DEL compounds, DEL1067-56-469 (A0) is the most potent one (KD = 430 nM, IC50 = 420 nM). Further optimization of A0 resulted in compound C10 with much improved potency (KD = 25 nM, IC50 = 150 nM). As an alternative approach, C10 was then converted into proteolysis targeting chimeras (PROTACs) in order to achieve deeper downregulation of the PIN1 protein in cancer cell lines. Unfortunately, neither PIN1 inhibitors nor PIN1 PROTACs demonstrated meaningful antiproliferation activity. In addition, siRNA knock-down experiments provided unfavorable evidence of PIN1 as an oncologic target. Our findings highlight the complexity of targeting PIN1 for cancer therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Recent advances of Pin1 inhibitors as potential anticancer agents

Cited by 2 publications

References 92 publications

Covalent binding of withanolides to cysteines of protein targets

Covalent binding of withanolides to cysteines of protein targets

Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs

Contact Info

Product

Resources

About